Survodutide vs Retatrutide (2026): A Head-to-Head Look at Two Pipeline Obesity Drugs
Survodutide (survodutide (BI 456906), Boehringer Ingelheim / Zealand Pharma) vs Retatrutide (retatrutide (LY3437943), Eli Lilly)
Last verified November 2026
The verdict
Survodutide and retatrutide are both investigational drugs that have not been approved by the FDA; all data come from separate phase 2 and phase 3 trials with different designs, populations, and durations, and no head-to-head comparison exists. In their respective phase 2 trials, retatrutide achieved −24.2% body weight loss at 48 weeks (12 mg dose, NEJM 2023), while survodutide reached −14.9% at 46 weeks (4.8 mg dose, Lancet Diabetes Endocrinol 2024), but these figures are not directly comparable across trials. Both now have published phase 3 obesity results (survodutide SYNCHRONIZE-1, NEJM 2026: −13.0% at 76 weeks on 6.0 mg), and survodutide has a dedicated liver-disease program (SYNCHRONIZE-MASLD, Nature Medicine 2026), giving it a meaningful edge for patients with fatty liver disease on GLP-1 drugs. Our survodutide explainer covers its dual GLP-1/glucagon design; retatrutide's triple mechanism (GLP-1/GIP/glucagon) is broader, and its TRIUMPH-1 before-and-after results showed −23.7% (9 mg) and −25.0% (12 mg) at 80 weeks versus −3.9% on placebo. Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Neither drug should be directly ranked from cross-trial data, and availability for either will depend on regulatory approval that has not yet occurred in the United States.
Side-by-side comparison
| Field | Survodutide | Retatrutide |
|---|---|---|
| Mechanism | GLP-1 / glucagon dual receptor agonist (GLP-1R + GcgR) | GLP-1 / GIP / glucagon triple receptor agonist (GLP-1R + GIPR + GcgR) |
| Peak weight loss — phase 2 | −14.9% at 46 wk (4.8 mg; PMID 38330987) — cross-trial only, not comparable to retatrutide figure | −24.2% at 48 wk (12 mg; PMID 37366315) — cross-trial only, not comparable to survodutide figure |
| Phase 3 weight-loss data | SYNCHRONIZE-1: −13.0% at 76 wk (6 mg; PMID 42253238, NEJM 2026) — published | TRIUMPH-1 (PMID 42814954, NEJM 2026): −23.7% (9 mg) and −25.0% (12 mg) at 80 wk vs −3.9% placebo |
| Trial stage / status | Phase 3 complete; SYNCHRONIZE program results published 2026 (obesity + MASLD) | Phase 3 TRIUMPH-1 and TRIUMPH-2 published 2026; US Biologics License Application submission planned Q1 2027 |
| MASH / liver-disease evidence | Phase 2 MASH (PMID 38847460, NEJM 2024): 62% MASH resolution, 34–36% fibrosis improvement at 4.8 mg vs 14% placebo; Phase 3 MASLD (PMID 42252333, Nature Medicine 2026): 84.2% achieved ≥30% liver fat reduction vs 24.3% placebo | No dedicated MASH or liver-fat clinical trial published; liver-related secondary outcomes not reported in phase-2 obesity paper |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| FDA approval status | Not FDA-approved; investigational (US) | Not FDA-approved; investigational (US) |
| Key differentiator | Most robust MASH / liver-disease evidence of any investigational obesity drug to date; phase 3 published | Highest published phase-2 obesity weight-loss magnitude; triple agonism adds GIP component absent in survodutide |
Frequently asked questions
Is retatrutide stronger than survodutide for weight loss?
Retatrutide showed −24.2% body weight loss in its phase-2 trial (NEJM 2023, 48 weeks, 12 mg), while survodutide showed −14.9% in its phase-2 trial (Lancet Diabetes Endocrinol 2024, 46 weeks, 4.8 mg). However, these trials had different designs, populations, doses, and endpoints, so the numbers are not directly comparable, and no head-to-head trial exists. In phase 3, retatrutide's TRIUMPH-1 reported −25.0% at 80 weeks on 12 mg and survodutide's SYNCHRONIZE-1 reported −13.0% at 76 weeks on 6.0 mg, again in different trials.
What is survodutide's main advantage over retatrutide?
Survodutide has the most extensive published liver-disease (MASH/MASLD) data of any investigational obesity drug. Its phase-2 MASH trial (NEJM 2024) showed 62% of patients achieved MASH resolution, and its phase-3 SYNCHRONIZE-MASLD trial (Nature Medicine 2026) showed 84.2% of survodutide patients achieved ≥30% liver fat reduction versus 24.3% on placebo. Retatrutide has no dedicated published liver/MASH trial.
How do survodutide and retatrutide differ mechanistically?
Survodutide is a GLP-1/glucagon dual receptor agonist, activating two receptors: GLP-1R (appetite/satiety) and GcgR (energy expenditure, liver fat reduction). Retatrutide is a triple agonist that additionally targets the GIP receptor (GIPR), which may contribute to its higher weight-loss magnitude in phase-2 data, though the clinical significance of the added GIPR agonism over a dual agent is not established from head-to-head data.
When might survodutide or retatrutide receive FDA approval?
Neither has been approved by the FDA as of November 2026. Survodutide's phase-3 SYNCHRONIZE-1 obesity trial published primary results in NEJM 2026, which could support an NDA filing; the SYNCHRONIZE-MASLD trial for liver disease also published in 2026. Retatrutide's TRIUMPH-1 (NEJM 2026) and TRIUMPH-2 (Lancet 2026) phase-3 trials are published, and Eli Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027. FDA decision dates for both drugs are not publicly confirmed.
Can you directly compare survodutide vs retatrutide weight-loss data?
No. All available comparisons are cross-trial only. The phase-2 trials differed in dose ranges, patient selection, trial duration, and endpoints. Cross-trial weight-loss numbers should not be used to conclude that one drug is definitively more effective than the other. Only a randomized head-to-head trial could establish comparative efficacy.
Is survodutide or retatrutide available to patients now?
Neither survodutide nor retatrutide is FDA-approved as of October 2026; both are investigational in the United States. Access is through clinical trials listed on ClinicalTrials.gov, plus, for retatrutide, a narrow single-patient expanded access program (NCT07629401) that a physician must request.
References
- 1.Jastreboff AM, Karol A, Stefanski A, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial New England Journal of Medicine. 2023. PMID: 37366315.
- 2.le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes & Endocrinology. 2024. PMID: 38330987.
- 3.Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis New England Journal of Medicine. 2024. PMID: 38847460.
- 4.le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity New England Journal of Medicine. 2026. PMID: 42253238.
- 5.Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Nature Medicine. 2026. PMID: 42252333.
- 6.Lawitz EJ, Fraessdorf M, Neff GW, et al. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis Journal of Hepatology. 2024. PMID: 38857788.
- 7.Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity N Engl J Med. 2026. PMID: 42814954.
- 8.Eli Lilly and Company Lilly reports second-quarter 2026 financial results (Form 8-K exhibit) U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
Related comparisons
- Wegovy vs Zepbound
- Ozempic vs Mounjaro
- Semaglutide vs Tirzepatide
- Rybelsus vs Ozempic
- Mounjaro vs Zepbound
- Foundayo vs Rybelsus
See the full drug-vs-drug verdict index or provider rankings.